Hem

Press release from Companies

Publicerat: 2022-05-27 14:42:54

Eevia Health Plc: Eevia Health Plc Interim Report Q1-2022

THE BOARD AND CEO OF EEVIA HEALTH PLC PRESENT THE INTERIM REPORT FOR QUARTER 1, 2022.

Significant events during the first quarter of 2022:

  • Net sales grew by 152% from KEUR 658 in Q4-21 to KEUR 1,659 in Q1-22. Eliminating raw material trading revenue of KEUR 42 in Q1-22 and non-recurring revenue effects of KEUR 143 during Q4-21, the adjusted net sales increased by 102%, from KEUR 803 in Q4-21 to KEUR 1,617 in Q1-22.
  • Compared to net sales in Q1-21, which was the record sales quarter so far for the Company with KEUR 3,234, net sales in Q1-22 were lower. However, raw material trading revenues dominated Q1-21. After excluding the trading revenues in Q1-21, the net sales from operations were only 15,6% lower in Q1-22 than in Q1-21, with KEUR 1,617 in Q1-22 compared to KEUR 1,917 in Q1-21.
  • The significant growth in Q1-22 compared to the previous quarter is evidence that the Company has primarily solved the production issues experienced during the latter half of 2021. While revenues in the first quarter fell slightly short of the record first quarter of last year, Eevia is well on track to continue its growth trajectory.
  • EBITDA for Q1-22 came in at KEUR -412 (KEUR -94), with a notable improvement in March, as explained below. Eevia has continued to see improvements in profitability so far in the second quarter, with April being close to break-even on the EBITDA level. The Company expects the improvements to continue into June. The improvements validate that the mitigation plan communicated in the Q4-2021 report has provided expected impacts.
  • The net result in Q1-22 was KEUR -611, which improved KEUR 419, or 41%, compared to Q4-21.
  • Eevia finalized several key equipment installations during Q1-22 and made critical adjustments to its production protocols. The new equipment provided significant improvements in yields and productivity during March and will continue to do so in the second quarter. The increased capacity has enabled Eevia to get back on track with the delivery schedule on sales contracts and removed a backlog that impacted sales since Mid 2021.
  • Some examples of the critical equipment installations during Q1-22 are:
    • Eevia almost doubled its chromatography capacity on February 20th.
    • A new decanter was installed in March (commissioned in April). It provides a 500% increase in capacity for liquid-solid separation of extraction masses and  significantly reduces processing time, which improvesboth yields and productivity.
    • New analytical measurement devices were installed in-line in the manufacturing process, such as two new absorbance meters and a new refractory meter (for measurements of solids). Compared to waiting many hours for lab results, these new measurement devices provide instant (real-time) measurement of the bioactive compound being extracted and purified. The instant measures significantly improve the process- and yield control.
  • A new Chief Manufacturing Officer, Harri Salo, joined Eevia in January. Mr. Salo’s competence has already had a significant impact on project management, improved operational control, and quality of production planning.
  • A new Chief Financial Officer, Gabriella Beni, joined Eevia in March. Ms. Beni has significant competence in financial administration and has strengthened Eevia’s financial control and profitability management ability.

Comments from our CEO

When considering the underlying performance trends, the first quarter of 2022 was hectic but satisfying. The quarter provided the significant improvements in yields and throughput we expected from to the mitigation plan we initiated in Q4-21. We made progress across the Board, increased our production output, ramped up product shipments, and developed the sales pipeline.

As set out in the introduction, the production team successfully finalized critical installations, which increased our manufacturing capacity and improved performance control. These new capabilities lay the foundation for leaps in yields, margins, productivity, and sales. The effects of these improvements came at the end of the quarter. Our financials do not yet fully reflect the underlying performance and progress in profitability.

The beginning of 2022 also saw a transformation of our management team. Two key recruits joined Eevia, Harri Salo as the new Chief Manufacturing officer and Gabriella Beni as our new Chief Financial Officer. The two strenghten our competence and capability for professionalmanagement and financial control of Eevia.

As for all economic activity these days, the market situation in our segment is somewhat more turbid than it has been in the last 18 months. The war in Ukraine, high inflation, labor shortages in crucial market territories, and continued global logistical challenges all create some uncertainty. However, these factors also constitute opportunities, as reliable manufacturers of nutrition products from suppliers in stable democracies are becoming even more valued by large international brand holders. We still see growth in the overall market. Major players have a positive outlook. We were pleased to see that the activity in the Vitafoods tradeshow in Geneva in early May was vigorous.

Our sales pipeline is in transformation driving growth from new products and customers. The new capacities have allowed Eevia to recover the backlog and catch up with the delivery schedule of contracts. That will enable us to be less restrictive with new leads and prospects. We are now opening our order acceptance for a broader range of products and new larger sales contracts.

As we proceed with further sales efforts towards our 2024 targets, we aim to maintain a stringent profitability focus, a target which is now easier to achieve with the recent production improvements.

Sincerely yours,

Stein Ulve

CEO

Key ratios

The table below shows the critical ratios for Q1-2022 and Q1-2021, and January to December 2021 and 2020:

             January 1st – March 31st January 1st– December 31st
2022 2021 2021 2020
Net sales, KEUR 1 659 3234 6 671 2 866
EBITDA, KEUR -412 -94 -2 099 -694
The net result of the period, KEUR -611 -169 -2 635 -1 023
Earnings per share, EUR* -0,04 -0,02 -0,16 -0,06
Shareholders' equity per share, EUR* 0,18 0,14 0,22 0,03
The average number of employees 26 29 28 9

Share related key rations have been calculated according to the following formulas:

Earnings per share, EUR                                                                          Net result of the period/15,973,356 shares

Shareholders’ equity per share, EUR                                                     Total equity/15,973,356 shares

The Share and shareholders

The total current number of shares amounts to 15,973,356 shares. Eevia has only one share series. The shareholders have authorized the Board of Directors to decide on the issuance of options to key employees with a maximum number of 706,000 shares. Based on this authorization, the Board has distributed 100,000 share options.

Future Reports

Interim report April – June 2022 (Q2) August 29th, 2022
Interim report July – September 2022 (Q3) November 25th, 2022
Year-End Report 2022 (Q4) February 24th, 2023 

Income Statement

(KEUR) Jan-Mar Jan-Mar Jan-Dec Jan-Dec
Ref. 2022 2021 2021 2020
 Net Sales 1 1 659 3 234 6 671 2 866
 Other income  2 57 0 15 117
 Total revenues 1 716 3 234 6 686 2 982
 Operating Expenses
 Material and external expenses  -1 445 -2 690 -5 847 -2 200
 Personnel expenses -482 -372 -1 502 -698
 Other operating expenses -201 -266 -1 437 -778
 Total Operating Expenses - 2 128 -3 327 -8 786 -3 676
 EBITDA -412 -94 -2 100 -694
 Depreciation -184 -84 -490 -229
 OPERATING PROFIT (LOSS) -596 -178 -2 589 -923
 Financial income and expenses -15 9 -46 -100
 PROFIT/-LOSS BEFORE TAXES -611 -169 -2 636 -1 023
 Taxes 0 0 0 0
 NET PROFIT/-LOSS FOR THE PERIOD -611 -169 -2 635 -1 023
  1. For Jan-Mar 2022, Net sales include KEUR 42 for sourcing and sale of raw materials as part of customer-provided financing. For Jan-Dec 2021, the amount related to the sale of materials for financing purposes was KEUR 1 317.
  2. For Jan-Mar 2022, Other income includes KEUR 57 capitalized own labor work associated with installations of capital assets.

Balance Sheet

ASSETS (KEUR) Mar-31 Mar-31 Dec-31 Dec-31
2022 2021 2021 2020
Fixed assets
Intangible assets 774 493 716 406
Tangible assets
Equipment, machines, and tools 2654 1 456 2 559 1 221
Total fixed assets 3 428 1 949 3 275 1 627
Other long-term receivables 24 24 24 24 
Current assets
Inventory 2 100 2 884 2 369 3 474
Trade receivables and other receivables 1 307 1 133 1 011 603
Cash at bank 365 524 1 859 678
Total current assets 3 772 4 540 5 239 4 755
TOTAL ASSETS 7 225 6 514 8 538 6 406
EQUITY AND LIABILITIES (KEUR) Mar-31 Mar-31 Dec-31 Dec-31
2022 2021 2021 2020
Equity
Share Capital 80 10 80 10
Reserve for invested unrestricted equity 8 802 4 402 8 802 3 167
Retained earnings/loss -5 381 -2 746 -2 746 -1 722
Profit (loss) for the period -611 -169 -2 635 -1 023
Total Equity 2 889 1 497 3 501 431
Long-term liabilities
Loans from credit institutions 406 170 406 170
Other long-term liabilities 0 82 0 82
Current liabilities
Other short-term loans 84 0 145 596
Advances received 2 397 2 963 2 939 3 945
Accounts payable 994 1 560 1 129 983
Other liabilities and accruals 455 242 419 198
Total liabilities 4 336 5 017 5 038 5 974
TOTAL EQUITY AND LIABILITIES 7 225 6 514 8 538 6 406

Cash Flow Statement

(KEUR) Jan-Mar Jan-Mar Jan-Dec Jan-Dec
2022 2021 2021 2020
Operating activities
Profit/-Loss before taxes -611 -169 -2 638 -1 023
Adjustments for items not included in the cash flow: 184 84 497 233
Cash flow before change in working capital -427 -85 -2 138 -790
Cash flow from changes in working capital: -668 -301 58 1 124
Increase (-) or decrease (+) in current interest-free receivables -296 -530 -408 -395
Increase (-) or decrease (+) in inventories 269 590 1 105 -3 159
Increase (+) or decrease (-) in current interest-free payables -640 -361 -640 4 678
Cash flow from operations before financial items and taxes -1095 -386 -2 080 335
Cash flow from extraordinary items 0 0 0 0
Cash flow after operating activities -1 095 -386 -2 080 335
Investment activities
Investments in intangible and tangible assets -338 -406 -2 138 -1 090
Cash flow from investment activities -337 -406 -2 138 -1 090
Financing activities
New Share issue 0 1136 5 606 0
New loans 0 0 400 848
Repayment of long-term borrowings -61 -497 -606 0
Cash flow from financing activities -61 639 5 400 848
Change in cash and equivalents -1 494 -154 1 182 93
Cash and cash equivalents at the beginning of the period 1 859 678 678 584
Cash and cash equivalents at the end of the period 365 524 1 859 678

Segmentation of sales and gross margin

Eevia's Net Sales in Q1-22 included KEUR 42 in trading revenues related to sourcing raw materials. The adjusted gross margin for Q1-22 decreased from 21 to 13%. The reported margin is average for the quarter. The margins in first half of the quarter were impacted by low potency berries. A major improvement to the protocols was finalized end of February. The gross margin in March was 28,5%. The increase in March was also due to improvements in yields and productivity related to the commissioning of new production equipment. Eevia maintains a long-term target gross margin level above 40% by 2024.

Segmentation of EBITDA, Jan-March 2022 Reported Income Statement
(KEUR) Ref. Operations Trading Non-recurring
 Net Sales 1 617 42 0 1 659
 Other income  57  0  0 57
 Total revenues 1 674 0 0 1 716
 Operating Expenses
 Material and external expenses  -1 403 -42 0 -1 445
 Personnel expenses -482 0  0 -482
 Other operating expenses 1 -151  0 -50 -201
 Total Operating Expenses - 2 036 -42 -50 -2 128
 EBITDA -362 0 -50 -412
Ref. Apr-Jun - 21 Jul-Sep - 21 Oct-Dec - 21 Jan-Mar - 22
 Product sales 1 369 560 801  1617
 Product standardization 2 -143
 Raw material sales 122 730 0 42
 Net Sales 1 491 1 289 658 1 659
Ref.  Apr-Jun - 21 Jul-Sep - 21 Oct-Dec - 21 Jan-Mar - 22
 Product sales 1 369 560 801 1 617
 Material and external expenses  -1 009 -422 -633 -1 403
 Gross margin 360 138 168 214
 Gross margin % 26 % 25 % 21 % 13 %
1) Non-recurring costs related to financing activities (commission, etc.)
2) The adjustment in Q4-21 was related to a product return which was resold at same price3) The gross margin in March was 28,5%

Basis of preparation

The financial information in this interim financial report has been prepared in accordance with the Finnish Accounting Act (30.12.1997/1336, as amended), Finnish Accounting Ordinance (30.12.1997/1339, as amended), and instructions and statements of the Accounting Board operating under the Ministry of Employment and the Economy (FAS) unless otherwise stated. The Company applies the same recognition and classification principles in this interim financial report as its financial statements for December 31st, 2021.

This interim financial report is unaudited.

Statement by the Board of Directors

The Board of Directors and the Chief Executive Officer do at this moment certify that this interim report contains a fair representation of the Company’s operations, financial position, and results and describes any significant risks and uncertainties the Company faces.

All statements of a forecasting nature in this report are based on the Company’s best assessments on the report’s publishing date. As with all forecasts, such statements contain risks and uncertainties, and the actual results can differ.

Seinäjoki, May 27th, 2022

The Board of Directors and the CEO of Eevia Health Plc

For additional information, please contact: 

Gabriella Beni, CFO  

Eevia Health Plc  

Mobile: +358.0.407.48.8666

Email: gabriella@eeviahealth.com

Eevia Health Plc

  • Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Aric Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.

    Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia’s other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.

    Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name EEVIA.

    To learn more, please visit  www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth. 

Läs mer hos Cision
Läs mer om Eevia Health Plc

Prenumeration